|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: KIAA1671 |
Gene summary for KIAA1671 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | KIAA1671 | Gene ID | 85379 |
| Gene name | KIAA1671 | |
| Gene Alias | KIAA1671 | |
| Cytomap | 22q11.23 | |
| Gene Type | protein-coding | GO ID | NA | UniProtAcc | Q9BY89 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 85379 | KIAA1671 | CA_HPV_3 | Human | Cervix | CC | 7.50e-05 | 8.45e-02 | 0.0414 |
| 85379 | KIAA1671 | CCI_1 | Human | Cervix | CC | 1.10e-11 | 1.12e+00 | 0.528 |
| 85379 | KIAA1671 | CCI_2 | Human | Cervix | CC | 3.06e-11 | 1.06e+00 | 0.5249 |
| 85379 | KIAA1671 | CCI_3 | Human | Cervix | CC | 1.64e-12 | 1.13e+00 | 0.516 |
| 85379 | KIAA1671 | HTA11_3410_2000001011 | Human | Colorectum | AD | 7.14e-06 | -2.52e-01 | 0.0155 |
| 85379 | KIAA1671 | HTA11_2487_2000001011 | Human | Colorectum | SER | 7.68e-09 | 7.89e-01 | -0.1808 |
| 85379 | KIAA1671 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.14e-09 | 7.04e-01 | -0.1954 |
| 85379 | KIAA1671 | HTA11_411_2000001011 | Human | Colorectum | SER | 2.12e-07 | 1.31e+00 | -0.2602 |
| 85379 | KIAA1671 | HTA11_2112_2000001011 | Human | Colorectum | SER | 4.09e-03 | 8.20e-01 | -0.2196 |
| 85379 | KIAA1671 | HTA11_83_2000001011 | Human | Colorectum | SER | 1.03e-03 | 6.60e-01 | -0.1526 |
| 85379 | KIAA1671 | HTA11_696_2000001011 | Human | Colorectum | AD | 6.80e-06 | 6.17e-01 | -0.1464 |
| 85379 | KIAA1671 | HTA11_866_2000001011 | Human | Colorectum | AD | 8.05e-03 | 4.60e-01 | -0.1001 |
| 85379 | KIAA1671 | HTA11_1391_2000001011 | Human | Colorectum | AD | 4.85e-05 | 6.42e-01 | -0.059 |
| 85379 | KIAA1671 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 2.02e-03 | -3.12e-01 | 0.294 |
| 85379 | KIAA1671 | F007 | Human | Colorectum | FAP | 1.77e-02 | -2.38e-01 | 0.1176 |
| 85379 | KIAA1671 | A002-C-010 | Human | Colorectum | FAP | 1.62e-02 | -1.93e-01 | 0.242 |
| 85379 | KIAA1671 | A001-C-207 | Human | Colorectum | FAP | 2.96e-02 | -6.96e-02 | 0.1278 |
| 85379 | KIAA1671 | A015-C-203 | Human | Colorectum | FAP | 2.98e-33 | -5.50e-01 | -0.1294 |
| 85379 | KIAA1671 | A015-C-204 | Human | Colorectum | FAP | 4.15e-08 | -4.02e-01 | -0.0228 |
| 85379 | KIAA1671 | A014-C-040 | Human | Colorectum | FAP | 1.12e-08 | -6.18e-01 | -0.1184 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| KIAA1671 | SNV | Missense_Mutation | novel | c.2581N>T | p.His861Tyr | p.H861Y | Q9BY89 | protein_coding | tolerated(1) | benign(0.342) | TCGA-BG-A0M0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| KIAA1671 | SNV | Missense_Mutation | novel | c.3163N>C | p.Ser1055Pro | p.S1055P | Q9BY89 | protein_coding | tolerated(0.22) | benign(0.046) | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| KIAA1671 | SNV | Missense_Mutation | rs770482979 | c.5102C>T | p.Ser1701Leu | p.S1701L | Q9BY89 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-BS-A0TJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| KIAA1671 | SNV | Missense_Mutation | novel | c.1567N>A | p.Glu523Lys | p.E523K | Q9BY89 | protein_coding | deleterious(0.02) | probably_damaging(0.909) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| KIAA1671 | SNV | Missense_Mutation | novel | c.817G>A | p.Glu273Lys | p.E273K | Q9BY89 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| KIAA1671 | SNV | Missense_Mutation | novel | c.1855G>A | p.Val619Met | p.V619M | Q9BY89 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| KIAA1671 | SNV | Missense_Mutation | novel | c.3422G>A | p.Arg1141His | p.R1141H | Q9BY89 | protein_coding | tolerated(0.23) | benign(0) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| KIAA1671 | SNV | Missense_Mutation | c.368G>A | p.Gly123Asp | p.G123D | Q9BY89 | protein_coding | tolerated(0.24) | benign(0.011) | TCGA-D1-A0ZS-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| KIAA1671 | SNV | Missense_Mutation | novel | c.843N>T | p.Arg281Ser | p.R281S | Q9BY89 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-D1-A15X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| KIAA1671 | SNV | Missense_Mutation | novel | c.127C>T | p.Pro43Ser | p.P43S | Q9BY89 | protein_coding | tolerated(0.11) | possibly_damaging(0.61) | TCGA-D1-A16G-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | taxol | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |